Pretargeted Radioimmunotherapy of Ovarian Cancer with ²²⁵Ac and an Internalizing Antibody

The field of nuclear medicine and theranostics has never been as vibrant as it is today ([1][1]–[3][2]). Over the last decade, largely because of the approval of several new radiopharmaceuticals by the U.S. Food and Drug Administration and the European Medicines Agency for diagnosis and treatment